ARTICLE | Company News
Serentis Inc., Surface Therapeutics Ltd. deal
October 8, 2007 7:00 AM UTC
Serentis acquired Surface for an undisclosed amount of stock. Serentis has four compounds in preclinical testing for dermatological indications. Surface's lead product is STP-01a/ST-441 AUREOSTAT, a p...